Report Highlights
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Report Includes
- 31 data tables and 63 additional tables
- An overview of the global market for the technologies for prevention and treatment of prostate cancer
- Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
- Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
- Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
- Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
- Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
- Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
- Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
- Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
- Profiles of leading market participants
Report Scope
This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.
Report Synopsis
| Report Metrics | Details | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2022 | ||||||||||||||
| Forecast period considered | 2023-2028 | ||||||||||||||
| Base year market size | $35.3 billion | ||||||||||||||
| Market size forecast | $56.4 billion | ||||||||||||||
| Growth rate | CAGR of 8.3% from 2023 to 2028 | ||||||||||||||
| Units considered | $ Millions | ||||||||||||||
| Segments covered | By Type, Subtype, and Region | ||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) | ||||||||||||||
| Key Market Drivers |
|
||||||||||||||
| Companies studied |
|
||||||||||||||
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Consulting Editor’s Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.
Report Highlights
The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%.
Report Includes
- An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
- Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
- Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
- Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
- Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
- Evaluation of prostate cancer treatment products by geography, race, and category
- Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
- Comprehensive company profiles of major players in the field.
Report Highlights
The global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.
This report provide:
- An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
- Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
- Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
- Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
- Evaluation of prostate cancer treatment products by geography, race, and category
- Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
- Comprehensive company profiles.
Related Reports
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets
The global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Melanoma Therapeutics: Global Markets
The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.
Recent Reports
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More